Tenax Therapeutics (TENX) Non-Current Debt (2011 - 2023)

Tenax Therapeutics (TENX) reported Non-Current Debt of $624302.0 for Q3 2023, little changed sequentially from $624302.0 in Q4 2022.

Tenax Therapeutics (TENX) Non-Current Debt (2011 - 2023) Analysis & Trends

Tenax Therapeutics (TENX) has 7 years of Non-Current Debt data on file, last reported at $624302.0 in Q3 2023.

For the quarter ending Q3 2023, Non-Current Debt changed N/A year-over-year to $624302.0; the trailing twelve-month figure through Sep 2023 stood at $624302.0 (changed N/A YoY), and the FY2022 full-year result was $624302.0, changed N/A from the prior year.
Non-Current Debt steadied at $624302.0 in Q3 2023, from $624302.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $624302.0 in Q4 2022 to a low of $31080.0 in Q1 2021.
A 4-year average of $292443.0 and a median of $175404.0 in 2020 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Tenax Therapeutics	67,856.40	67,856.40	-	-

Download Data